These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Kromann CB; Ibler KS; Kristiansen VB; Jemec GB Acta Derm Venereol; 2014 Sep; 94(5):553-7. PubMed ID: 24577555 [TBL] [Abstract][Full Text] [Related]
10. Hidradenitis suppurativa: importance of early treatment; efficient treatment with electrosurgery. Aksakal AB; Adişen E Dermatol Surg; 2008 Feb; 34(2):228-31. PubMed ID: 18093196 [TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of hidradenitis suppurativa. Fernández-Vozmediano JM; Armario-Hita JC Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838 [TBL] [Abstract][Full Text] [Related]
12. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. Schrader AM; Deckers IE; van der Zee HH; Boer J; Prens EP J Am Acad Dermatol; 2014 Sep; 71(3):460-7. PubMed ID: 24880664 [TBL] [Abstract][Full Text] [Related]
13. Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. Bui TL; Silva-Hirschberg C; Torres J; Armstrong AW J Am Acad Dermatol; 2018 Feb; 78(2):395-402. PubMed ID: 29056237 [TBL] [Abstract][Full Text] [Related]
15. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. McMillan K Am J Epidemiol; 2014 Jun; 179(12):1477-83. PubMed ID: 24812161 [TBL] [Abstract][Full Text] [Related]
16. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Giamarellos-Bourboulis EJ; Antonopoulou A; Petropoulou C; Mouktaroudi M; Spyridaki E; Baziaka F; Pelekanou A; Giamarellou H; Stavrianeas NG Br J Dermatol; 2007 Jan; 156(1):51-6. PubMed ID: 17199566 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Mekkes JR; Bos JD Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504 [TBL] [Abstract][Full Text] [Related]
18. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. Cosmatos I; Matcho A; Weinstein R; Montgomery MO; Stang P J Am Acad Dermatol; 2013 Mar; 68(3):412-9. PubMed ID: 22921795 [TBL] [Abstract][Full Text] [Related]
19. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. Gold DA; Reeder VJ; Mahan MG; Hamzavi IH J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875 [TBL] [Abstract][Full Text] [Related]
20. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. Shlyankevich J; Chen AJ; Kim GE; Kimball AB J Am Acad Dermatol; 2014 Dec; 71(6):1144-50. PubMed ID: 25440440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]